Latest Director Appointments News

Investor Centre’s FY2025 report lays bare the financial strain behind its proposed revival: revenue collapsed, cash fell to just $3,320 and liabilities exceeded assets by $3.81 million. The company is now relying on an unsecured Lake Volta Investments facility and a non-binding restructuring plan after its brokerage subsidiary lost its AFSL.

Memphasys has signed a three-year exclusive distribution agreement covering the Czech Republic, Slovakia and Kazakhstan, with minimum purchases worth approximately A$674,000. The deal expands Felix’s European footprint while adding dedicated commercial leadership in the region.

Galilee Energy posted a $5.42 million loss for FY2026 amid heavy investment in its US Zydeco Gas Project and progressing the sale of its Australian Glenaras asset. The company is pivoting to US operations with drilling underway and a $3.5 million placement announced.

Argo Investments reported a stable $260.2 million profit for FY2026 with fully franked dividends rising to 38.5 cents per share. The LIC maintains a conservative investment approach, low costs, and strong governance as it marks 80 years.

Pengana Capital Group has lodged a formal application with the Takeovers Panel contesting the legitimacy and disclosure of Pengana International Equities’ recent capital management moves, including a contentious buy-back and rights issue.

Rhythm Biosciences marked its transition to commercialisation with first sales of ColoSTAT® and geneType™ tests, despite a 55% increase in loss to $5.93 million. The company expanded market access and secured manufacturing agreements, while NHS England began evaluating ColoSTAT® for bowel cancer screening.

Winton Land’s governance is under strain after independent directors Steven Joyce and Guy Fergusson resigned citing conflicts with the majority shareholder. The board must urgently appoint new independent directors to maintain NZX compliance and avoid potential trading suspension.

TALi Digital Limited (ASX: TD1) posted a 416% jump in revenue for FY26 but also recorded a $2.2 million loss driven by a $1.3 million impairment of its YCDI! intangible assets. The company is pursuing growth through AI-focused acquisitions and a $3.3 million capital raise.

TradeWindow is positioning itself for a primary ASX listing, appointing two seasoned Australian logistics experts to its board and reshaping its executive team to deepen market expertise and meet listing requirements.

Macmahon Holdings delivered a tenth consecutive year of growth with revenue up 7.9% to $2.6 billion and net profit after tax soaring 36.8% to $101.1 million, underpinned by strong contract wins and operational discipline.

ASX Limited reported a 13.3% rise in operating revenue to $1.25 billion for FY26, with underlying net profit up 5.2%, despite a 3.5% dip in statutory profit due to significant one-off costs including a $20.5 million ASIC penalty. The company declared a fully franked final dividend of 104.7 cents per share and appointed Anthony Attia as CEO.

Anteris Technologies posted a $51.7 million loss in H1 2026 amid ramped-up R&D and clinical trial activity, supported by a $320 million capital raise and Medicare reimbursement for its DurAVR heart valve trial.